Asst Prof Chan Yong Sheng Jason

Dr Jason Chan is a Senior Consultant Medical Oncologist at the National Cancer Centre Singapore and Assistant Professor at Duke-NUS Medical School. He concurrently serves as Director of the Cancer Discovery Hub and Director of Medical Oncology Research at the National Cancer Centre Singapore, as well as Director of Research at the SingHealth Duke-NUS Blood Cancer Centre. At the national level, he serves as Platform Lead for the Singapore Translational Cancer Consortium.

Dr Chan has special interests in lymphomas and rare cancers including sarcomas and melanomas. His key research interests lie in unravelling the molecular pathobiology of cancers with the aim of improving clinical care of patients inflicted with these diseases. He was awarded the NMRC Transition Award in 2021 and SingHealth Distinguished Young Researcher Award in 2023.

He is a strong advocate of education and is heavily involved in the mentorship of medical students, clinical residents and budding researchers. He serves as Council Member of the SingHealth Duke-NUS Academy of Clinician-Scientists, Innovators & Investigators. For his efforts, he has been conferred the National University of Singapore Dean's Award for Teaching Excellence and SingHealth RiSE Outstanding Faculty Awards.

• SingHealth-SMU Graduate Diploma in Healthcare Management & Leadership (GDHM), 2025
• Duke-NUS Graduate Certificate Programme in Health Services Innovation (GCHSI), 2024
• PhD (Cancer Biology), Cancer Science Institute of Singapore, 2020
• Fellow of Academy of Medicine Singapore (FAMS, Medical Oncology), 2018
• Specialist Accreditation in Medical Oncology, Ministry of Health Singapore, 2017
• MMed (Internal Medicine), National University of Singapore, 2012
• MRCP, Royal College of Physicians (UK), 2012
• MBBS, National University of Singapore, 2008  

• Head and Senior Consultant, Lymphoma and Sarcoma Medical Oncology, NCCS
• Council Member, SingHealth Duke-NUS Academy of Clinician-Scientists, Innovators & Investigators (2025 – Present)
• Director of Medical Oncology Research (DMO Research), NCCS (2024 – Present)
• Director of Research, SingHealth Duke-NUS Blood Cancer Centre (2024 – Present)
• Director, Cancer Discovery Hub, NCCS (2021 – Present)
• Executive Committee/Platform Lead, Singapore Translational Cancer Consortium (2022 – Present)
• Clinical Advisor, SingHealth Duke-NUS Institute of Biodiversity Medicine (BD-Med) (2021 – Present)
• Executive Committee, TargEted TheRApy for blooD Cancer (TETRAD II) (2021 – 2026)
• Assistant Professor, Duke-NUS Medical School (2019-present)
• Faculty Member, SingHealth Medical Oncology Residency Program (2018-present)
• Physician Faculty Member, SingHealth Advanced Internal Medicine Residency Program (2022-present)
• Mentor, SingHealth Internal Medicine Residency Program (2017-present)
• Clinical Lecturer, National University of Singapore (2015-present)
• Member, Singapore Society of Oncology (SSO), 2014
• Member, American Society of Hematology (ASH), 2018
• Member, Connective Tissue Oncology Society (CTOS), 2017
• Member, European Society of Medical Oncology (ESMO), 2015
• Member, American Society of Clinical Oncology (ASCO), 2014
• Member, Singapore Medical Association (SMA), 2008
• Member, American Association for Cancer Research (AACR), 2006  

• SingHealth Duke-NUS AMC Blaze Award, 2026
• SingHealth Excellence Awards for Distinguished Young Researcher Award, 2023
• ESMO Travel Award, 2020 and 2023
• NCCS Research Publication Award, 2022
• Singapore National Medical Research Council Transition Award, 2021
• SingHealth RiSE Outstanding Faculty Award, 2019 and 2020
• SingHealth and NCCS 10 Years Long Service Award, 2020
• Singapore Health Quality Service Awards (Silver), 2019
• SingHealth Publish! Award, 2019
• SingHealth Duke-NUS Research Day Appreciation Award - Bunsen Burner Award, 2017
• Nurturing Clinician Scientist Scheme, SingHealth Duke-NUS Academic Medical Centre, 2017
• SingHealth RiSE Outstanding Resident Award, 2016 and 2017
• National University of Singapore Dean's Award for Teaching Excellence, 2016
• Junior Pitch For Funds Award, SingHealth Internal Medicine Academic Clinical Program, 2014
• SingHealth RiSE Award for Outstanding Performance for In-Training/Intermediate Exams, 2013
• SingHealth Internal Medicine Residency Research Symposium Best Oral Presentation Award, 2013
• Frontiers in Cancer Science Conference Best Poster Award (co-author), 2009
• National Healthcare Group Annual Scientific Meeting Best Oral Presentation Award (Merit), 2009
• National Healthcare Group International Conference Award, 2009
• National University of Singapore Outstanding Undergraduate Researcher Prize, 2007 and 2008
• Jane Prize in Paediatrics, 2007
• Elsevier Health Sciences Award, 2007  

• POLAR: Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)
• BCV-NL01: A Phase 1b/2, Open-label, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and its Efficacy in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

• Chan JY, et al. Preclinical activity of brincidofovir in peripheral T-cell and NK/T-cell lymphoma. BMC Medicine. 2026;24(1):147.
• Ge AY, …, Chan JY, et al. Global access to commercial CAR T cells: A cross-sectional study of health technology assessment in the G20. Global access to chimeric antigen receptor T-cell therapies: A cross-sectional study of health technology assessment of CAR T across G20 countries. Blood. 2026;147(14):1521-1531.
• Lee JY, …, Chan JY. High clinical actionability of a pan-cancer tissue-based combined DNA and RNA next generation sequencing assay in a diverse Asian population. NPJ Precision Oncology. 2025;9(1):347.
• Huang C, …, Chan JY, et al. Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma. Cancer Discovery. 2025;15(12):2450-2467.
• Chan JY, et al. Single-cell landscape of idiopathic Multicentric Castleman Disease in identical twins. Blood. 2024:blood.2023021992.
• Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024;17(1):38.
• Lim RMH, …, Chan JY. Molecular and immune pathobiology of human angiosarcoma. Biochim Biophys Acta Rev Cancer. 2024;1879(5):189159.
• Loh JW, …, Chan JY. Spatial transcriptomics reveal topological immune landscapes of Asian head and neck angiosarcoma. Commun Biol. 2023;6:461.
• Chan JY, et al. On the clinical implications of systemic and local immune responses in human angiosarcoma. NPJ Precision Oncology 2021;5(1):11.
• Chan JY, et al. Multi-omic analysis and immunoprofiling reveals distinct subtypes of human angiosarcoma. Journal of Clinical Investigation 2020;130(11):5833-5846.
• Lim JQ, …, Chan JY, et al. Whole-genome Sequencing Identifies Responders to Pembrolizumab in Relapse/Refractory Natural-killer/T Cell Lymphoma. Leukemia 2020 Dec;34(12):3413-3419.
• International NKTCL Working Group. A Genome-wide association study identifies two novel susceptibility loci for extranodal natural killer T-cell lymphoma. Lancet Oncology 2020;21(2):306-316.
• Chan JY, et al. Whole exome sequencing identifies recessive germline mutations in FAM160A1 in familial NK/T cell lymphoma. Blood Cancer Journal 2018;8(11):111.
• Tan J, …, Chan JY, et al. Genomic landscapes of breast fibroepithelial tumors. Nature Genetics 2015;47(11):1341-5.
• Subramaniam MM, Chan JY, et al. Dedifferentiated liposarcoma with unusual Kaposiform morphology and whorl formation masquerading a Kaposi sarcoma: Diagnostically challenging case confirmed by cytogenetic and TP53 mutation analyses. Journal of Clinical Oncology 2013;31(7):e101-5.